GB Sciences Files a Nonprovisional Patent Application for Cannabis-Based Anti-Inflammatory Therapies Including Arthritis, Asthma, Eczema and More

LAS VEGAS, Feb. 5, 2018 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) has filed a nonprovisional patent application to protect its cannabinoid-containing complex mixtures for the treatment of inflammatory disorders. The new patent application claims the benefit of GB Sciences' provisional patent previously filed on February 1, 2017; plus, additional data describing their mechanism of action and further supporting their claims. Inflammatory disorders, such as arthritis, asthma, eczema, psoriasis, Crohn's disease and Inflammatory Bowel Disease, represent a serious health burden in the US with over $200 billion spent annually. New cannabis-based therapies could significantly help both patients and society.

"Filing this nonprovisional patent signifies our passage to the next phase in the development of these cannabis-based anti-inflammatory compounds, which have the potential to alleviate patient suffering," explains Dr. Andrea Small Howard, Chief Science Officer of GB Sciences, Inc. "We look forward to commercializing the multiple disease-specific anti-inflammatory formulations in this patent application through different channels; including one potential pharmaceutical formulation that may be applied to an orphan indication and another with a nutraceutical-compliant formulation. GB Sciences also plans to develop a series of distinct anti-inflammatory formulations for sale in cannabis dispensaries. Development through different regulatory pathways and sales channels allows us to get some of these therapies to patients quicker and to implement a diversified sales strategy."

"GB Sciences is committed to developing products that improve peoples' lives and new anti-inflammatory products are needed as these conditions increase in prevalence," said John Poss, CEO and Chairman of GB Sciences, Inc. "Providing our patients with cannabis-based products that are designed for dispensary sales will benefit patients in the near term."

About GB Sciences, Inc.

GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company's goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements.  Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control.  It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements.  Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov.  All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Note:  Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.

Contact Information

Corporate:

GB Sciences, Inc., 3550 West Teco Ave., Las Vegas, NV 89118
866-721-0297, or 
Tom Arcuragi, EVP, [email protected]

SOURCE GB Sciences, Inc.